IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01097460MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
NCT01265927A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
NCT01384253Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
NCT01649271Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
NCT00950742Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.